

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. S0 3167/4Z	
Applicant(s): John P. McKearn, et al.					
Serial No. 09/857,873	Filing Date October 5, 2001	Examiner J. D. Goldberg	Group Art Unit 1614		
Invention: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENT AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA					
RECEIVED					
TO THE ASSISTANT COMMISSIONER FOR PATENTS: APR 30 2003 Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	11 -	20 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-1025 A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. </div> <div style="text-align: right;"> Dated: 4/22/03 </div> </div> <div style="margin-top: 20px;"> <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center;"> Signature James M. Warner, Reg. No. 45,199 </div> </div> </div>					
<div style="border: 1px solid black; padding: 5px;"> I certify that this document and fee is being deposited on 4/22/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. <div style="text-align: center; margin-top: 10px;"> Signature of Person Mailing Correspondence Sharon Rudebeck Typed or Printed Name of Person Mailing Correspondence </div> </div>					

1614

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): John P. McKearn, et al.

Docket No.

3167/4Z

Serial No.

09/857,873

Filing Date

October 5, 2001

Examiner

J.D. Goldberg

Group Art Unit

1614

Invention: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE
ANTINEOPLASTIC AGENT AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA



RECEIVED

APR 30 2003

TECH CENTER 1600/2900

I hereby certify that this Amendment Transmittal, Amendment and Post card

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

April 22, 2003

(Date)

Sharon Rudebeck

(Typed or Printed Name of Person Mailing Correspondence)

A handwritten signature in cursive script that reads "Sharon Rudebeck".

(Signature of Person Mailing Correspondence)



PATENT

10/B
3167/4/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF) GROUP ART UNIT: 1614
J. P. McKearn et al.)
SERIAL NO. 09/857,873) EXAMINER: J. D. Goldberg
FILED: OCTOBER 5, 2001) DATE: APRIL 22, 2003

Bet
5-2-03

Title: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND
ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION
THERAPY IN THE TREATMENT OF NEOPLASIA

I hereby certify that this correspondence is being deposited with the United States Postal
Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks,
Washington D.C., 20231 on April 22, 2003

RECEIVED

Sharon Rudebeck

Sharon Rudebeck

Date: *4/22/03*

APR 30 2003

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

UNDER 37 C.F.R. § 1.111

I. INTRODUCTORY COMMENTS

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

This letter is in response to the Office Action dated March 26, 2003, having a
Shortened Statutory Period for Response which is set to expire on April 26, 2003. This
response is timely filed. Please charge any appropriate fees to Deposit Account No. 19-
1025.

It is requested that the requirements under 37 CFR 1.121 be waived according to
the Notice of February 25, 2003 (Official Gazette of the USPTO, Vol. 1267 Number 4)
titled "Amendments in a Revised Format Now Permitted".